• linkedin
  • Increase Font
  • Sharebar

    Year-2 Protocol T data paints different scenario from year-1



    Vision gains from baseline were sustained through 2 years, and the differences that favored aflibercept over ranibizumab in the worse baseline vision group had dissipated by Year 2, he said.

    “The implication of the increased rate of APTC events with ranibizumab found in this study is uncertain and inconsistent with many prior trials and warrants further study,” Dr. Wells said. Any post-hoc analyses “should be viewed with caution” but “can provide insights that might be useful as clinicians apply these study results to their practices.”


    John A. Wells, MD

    E: [email protected]

    Dr. Wells is an investigator for Genentech and Regeneron. This article was adapted from a presentation Dr. Wells delivered at Retina Subspecialty Day prior to the 2016 American Academy of Ophthalmology meeting.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';